Late Breaking Abstract - Results from a phase 1, randomized, double-blind, single and multiple ascending oral dose study characterizing the PK, safety, and target engagement of the Rho kinase 1 and 2 inhibitor ROC-101 in healthy volunteers - Amsterdam 2025

Pulmonary arterial hypertension: new molecular pathways and new therapeutic insights

Chair(s): Mark Toshner, Johad Khoury

Session type: Poster session

Late Breaking Abstract - Results from a phase 1, randomized, double-blind, single and multiple ascending oral dose study characterizing the PK, safety, and target engagement of the Rho kinase 1 and 2 inhibitor ROC-101 in healthy volunteers

James Hui

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Second- and Third-generation BCR-ABL Tyrosine-Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent new-user Population-based Cohort Study

Clément Jambon-barbara

Poster

Abstract

Targeting adenylyl cyclase isoform 6: novel therapy for pulmonary hypertension

Saeid Maghsoudi

Abstract

Effect of combined 5-HT1B receptor antagonist and serotonin reuptake inhibitor LY393558 on isolated pulmonary artery in monocrotaline-induced rat pulmonary arterial hypertension model

Gökçen Telli

Poster

Abstract

Prognostic Significance of Heart Rate Recovery After 6-Minute Walk Test in Pulmonary Arterial Hypertension

Sojirat Wiwatcharoenkul

Abstract

The role and mechanism of gut microbial metabolite trimethylamine N-Oxide in the occurrence and development of right heart failure

Qianwen Bai

Poster

Abstract

The role of SOX17 in the shear stress response of the arterial endothelium

Jurjan Aman

Poster

Abstract

Hypoxic induction of SGLT2 promotes pulmonary hypertension involving endothelial NADPH oxidases and the HIPPO pathway effector YAP

Xiaoyi Zhan

Poster

Abstract

IRG1/Itaconate axis-mediated inter-organ communication: unraveling bone marrow dynamics in pulmonary hypertension

Golnaz Hesami

Poster

Abstract

Long-term survival in patients with pulmonary arterial hypertension with comorbidities stratified by risk classification.

Misaki Kanezawa

Poster

Abstract

ALK1:BMPRII receptor clustering by an agonist bispecific antibody (rDIAG723) prevents PAH development in the rat sugen hypoxia model

Andrew Sullivan

Poster

Abstract

Increased bone morphogenetic protein 10 in precapillary pulmonary hypertension patients

Jessie Van Wezenbeek

Poster

Abstract

Right Ventricular Response to Pulmonary Hypertension: Sex- and Strain-Dependent Differences in Sugen5416 and Hypoxia Models

Sailun Wang

Poster

Abstract

Circulating biomarkers for discriminating pulmonary arterial hypertension and pulmonary veno-occlusive disease

Jan-christopher Kamp

Poster

Abstract

Endothelial USP2a-METTL16 loop amplifies IL-6 signaling in pulmonary hypertension

Hanqing Zhu

Poster

Abstract

The impact of amyloid-beta and phosphorylated tau 217 on pulmonary hypertension associated cognitive dysfunction

Ping Yuan

Abstract

Decoding the impact of epicardial adipose tissue on right ventricular failure in pulmonary arterial hypertension

Manon Mougin

Poster

Abstract

FHL2 is a novel target in pulmonary arterial hypertension

Cacharel Nadeem

Poster

Abstract

Preclinical evaluation of a novel vector for Pulmonary Hypertension diagnosis and treatment

Harm Jan Bogaard

Poster

Abstract

James Hui

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}